ABSTRACT
The continuous Chloroquine (CQ) use resulted in intensified parasite resistance to
CQ. This led to adaptation of artemisinin based combination therapy (ACT) as the
first-line antimalarial drug for the treatment of uncomplicated malaria in January,
2005. Despite the replacement, anecdotal evidences suggest that CQ is still being
used in many communities in Ghana. This study was conducted to investigate the
continuous use of CQ and its effect on CQ resistance markers in the Central
Region, Ghana. Using questionnaire, mystery buying and Sakar-Solomon’s urine
CQ assay method, a survey was conducted to ascertain the continuous use of CQ.
The prevalence of point mutations of Pfcrt and Pfmdr1 genes were assessed from
Plasmodium falciparum infected blood samples of subjects, employing the nested
PCR and RFLP techniques. Out of 618 subjects, 2.43% of the subjects preferred
to use CQ injection while 0.49% confirmed the use CQ for treatment of malaria.
Out of 69 community pharmacies and chemical shops surveyed, 14.49% had
stocks of CQ which were being dispensed. Qualitative urine assay revealed that
16.9% out of 444 participants had CQ in their urine samples. Of the 214 P.
falciparum isolates, 71.9% were found to have the K76T mutation of Pfcrt. The
risk of becoming infected with CQ resistant P. falciparum strain with mutation at
position 76 of pfcrt in people who had chloroquine in their urine was thirteen
times [OR=12.63, 95%CI (8.57-18.62)], p
ASARE, K (2021). EVALUATION OF PLASMODIUM FALCIPARUM CHLOROQUINE RESISTANT MARKERS IN SELECTED HEALTH FACILITIES IN CENTRAL REGION AFTER SEVEN YEARS OF BANNING CHLOROQUINE TREATMENT IN GHANA. Afribary. Retrieved from https://afribary.com/works/evaluation-of-plasmodium-falciparum-chloroquine-resistant-markers-in-selected-health-facilities-in-central-region-after-seven-years-of-banning-chloroquine-treatment-in-ghana
ASARE, KWAME "EVALUATION OF PLASMODIUM FALCIPARUM CHLOROQUINE RESISTANT MARKERS IN SELECTED HEALTH FACILITIES IN CENTRAL REGION AFTER SEVEN YEARS OF BANNING CHLOROQUINE TREATMENT IN GHANA" Afribary. Afribary, 01 Apr. 2021, https://afribary.com/works/evaluation-of-plasmodium-falciparum-chloroquine-resistant-markers-in-selected-health-facilities-in-central-region-after-seven-years-of-banning-chloroquine-treatment-in-ghana. Accessed 24 Apr. 2024.
ASARE, KWAME . "EVALUATION OF PLASMODIUM FALCIPARUM CHLOROQUINE RESISTANT MARKERS IN SELECTED HEALTH FACILITIES IN CENTRAL REGION AFTER SEVEN YEARS OF BANNING CHLOROQUINE TREATMENT IN GHANA". Afribary, Afribary, 01 Apr. 2021. Web. 24 Apr. 2024. < https://afribary.com/works/evaluation-of-plasmodium-falciparum-chloroquine-resistant-markers-in-selected-health-facilities-in-central-region-after-seven-years-of-banning-chloroquine-treatment-in-ghana >.
ASARE, KWAME . "EVALUATION OF PLASMODIUM FALCIPARUM CHLOROQUINE RESISTANT MARKERS IN SELECTED HEALTH FACILITIES IN CENTRAL REGION AFTER SEVEN YEARS OF BANNING CHLOROQUINE TREATMENT IN GHANA" Afribary (2021). Accessed April 24, 2024. https://afribary.com/works/evaluation-of-plasmodium-falciparum-chloroquine-resistant-markers-in-selected-health-facilities-in-central-region-after-seven-years-of-banning-chloroquine-treatment-in-ghana